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Abstract
Microparticles are membrane vesicles with pro-inflammatory properties. Circulating levels of microparticles have previously
been found to be elevated in patients with metabolic syndrome (MetS). The present study aimed to evaluate the effects of
in vivo treatment with microparticles, from patients with MetS and from healthy subjects (HS), on ex vivo vascular function in
mice. Microparticles isolated from MetS patients or HS, or a vehicle were intravenously injected into mice, following which
vascular reactivity in response to vasoconstrictor agonists was assessed by myography with respect to cyclo-oxygenase
pathway, oxidative and nitrosative stress. Injection of microparticles from MetS patients into mice induced vascular hypo-
reactivity in response to serotonin. Hypo-reactivity was associated with up-regulation of inducible NO-synthase and
increased production of NO, and was reversed by the NO-synthase inhibitor (NG-nitro-L-arginine). The selective COX-2
inhibitor (NS398) reduced the contractile effect of serotonin in aortas from mice treated with vehicle or HS microparticles;
however, this was not observed within mice treated with MetS microparticles, probably due to the ability of MetS
microparticles to enhance prostacyclin. MetS microparticle-mediated vascular dysfunction was associated with increased
reactive oxygen species (ROS) and enhanced expression of the NADPH oxidase subunits. Neutralization of the pro-
inflammatory pathway Fas/FasL completely prevented vascular hypo-reactivity and the ability of MetS microparticles to
enhance both inducible NO-synthase and monocyte chemoattractant protein-1 (MCP-1). Our data provide evidence that
microparticles from MetS patients induce ex vivo vascular dysfunction by increasing both ROS and NO release and by
altering cyclo-oxygenase metabolites and MCP-1 through the Fas/FasL pathway.
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Introduction
Metabolic syndrome (MetS) is associated with glucose intoler-
ance, obesity, ageing, elevated blood pressure and dyslipidaemia,
all of which are risk factors associated with cardiovascular
morbidity and mortality [1,2]. The prevalence of MetS is
increasing and continues to provide challenges for medical
research beyond its clinical and public health importance.
The pathophysiology of MetS seems to be largely attributable to
insulin resistance with the implication of excessive flux of fatty
acids [1,2], but also to a pro-inflammatory state resulting from the
production of cytokines from adipocytes and macrophages
[1,3,4,5]. Thus, increased inflammatory factors and reactive
oxygen species (ROS) are associated with detrimental cardiovas-
cular alterations linked to MetS. Inflammation is orchestrated by
the interactions between inflammatory cells (such as leukocytes)
and vascular cells (endothelial and smooth muscle cells) which
under activation or apoptosis (for example) lead to the release of
circulating microparticles (MPs) [6,7].
MPs are membrane vesicles with pro-coagulant and pro-
inflammatory properties [6,7]. The mechanism of MP formation
is complex and has yet to be clearly elucidated, due to cell type and
stimuli specificity. However, evidence suggest that following cell
activation or apoptosis, MP formation occurs due to the sustained
elevation in cytosolic calcium concentration in addition to the
consequent activation of calpain and protein kinases and the
inhibition of phosphatases. In addition to MP formation, these
changes result in cytoskeletal reorganization and membrane
blebbing [6,8,9,10]. The mechanism of MPs clearance from the
circulation is currently unknown, but due to their small size, MPs
are believed to be more readily diffusible than cells, and are able to
escape phagocytosis [11].
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MPs are present in the blood of healthy individuals, however
MP formation increases with diseased states, such as MetS [12],
sepsis [13], preeclampsia [14], and sleep apnea syndrome [15].
MP release also increases in various clinical situations associated
with thrombosis, as well as in diabetic patients, thereby
strengthening the hypothesis that MPs may play an important
role in these diseases. Indeed, MPs can be considered as vectors of
biological messages, such as induction of endothelial and vascular
dysfunctions or platelet activation [6,7].
Recently, we reported that MetS patients display elevated
circulating levels of MPs compared to healthy subjects, especially
those from pro-coagulant (Annexin V+), endothelial, platelet and
erythrocyte origins; furthermore these MPs are associated with
endothelial dysfunction both in vitro and in vivo [12]. Moreover,
Arteaga et al. [16] reported a marked elevation of endothelial-
derived MP levels as well as activation markers of both leukocytes
and platelets in patients with MetS compared to controls. In
addition, they observed an increase in binding of endothelial- and
platelet-derived MPs to leukocytes within MetS patients. Finally,
Chironi et al. [17] found that leukocyte-derived MP level was
higher in MetS patients than in healthy individuals and that
leukocyte-derived MP level increased concomitantly with the
number of MetS components.
Nevertheless, the effects of MPs from MetS patients on
vascular reactivity in response to vasoconstrictor agonists have
not yet been assessed. Therefore, the aims of the present study
were to: 1) assess the effect of circulating MPs from MetS patients
on vascular reactivity with special interest in oxidative and
nitrosative stresses in vivo, and 2) identify cellular mechanism(s)
underlying these effects. Amongst the known pro-inflammatory
pathways, we focused our interest on the potential involvement of
Fas/FasL pathway. Fas is a type I membrane protein belonging
to the TNF receptor family that initiates an apoptotic signal when
bound to its ligand, FasL [18]. Functionally, FasL has been
demonstrated to be a pro-inflammatory factor that is implicated
in pathophysiological processes of various cardiovascular diseases
such as coronary heart disease, arteriosclerosis, as well as
ischemia-reperfusion injury [19]. Fas/FasL interaction is involved
in apoptosis of vascular smooth muscle cells [20] and the
expression of a specific program of inflammatory genes in the
same cells [21,22]. It should be noted that we previously reported
that lymphocytic MPs interact with smooth muscle cells through
the Fas/FasL pathway, evoke NF-kB activation, which in turn
up-regulates iNOS and COX-2 expression leading to the
production and release of the vasodilatory factors, NO and
prostacyclin [23].
Methods
Ethics Statement
The human study was approved by the Ethics Committee of the
University Hospital of Angers (France) as the NUMEVOX cohort
(registration number: 200704256). The NUMEVOX cohort is also
referenced at Clinicaltrials.gov (Impact of Adipose Tissue
Repartition on the Time Course of Vascular Dysfunction - the
NUMEVOX Cohort). The investigation conforms to the princi-
ples outlined in the Declaration of Helsinki. All subjects agreed to
participate in the follow-up study by written consent.
The University of Angers Ethics Committee approved the
animal protocol followed in the present study (CEEA.2009.9). All
animal studies were carried out using approved institutional
protocols and conformed by the Guide for the Care and Use of
Laboratory animals published by US National Institutes of Health
(NIH Publication No. 85-23, revised 1996).
Subjects
We included patients with MetS from the Department of
Endocrinology and Nutrition of the University Hospital of Angers.
Patients were eligible for inclusion, according to the National
Cholesterol Education Program-Adult Treatment Panel III
(NCEP-ATP III) [24,25], when they had at least three criteria
out of the five following: (I) waist circumference .102 or 88 cm
for men and women, respectively; (II) high systolic and diastolic
pressures .130/85 mm Hg; (III) fasting glycemia .5.5 mmoll21;
(IV) triglycerides .1.65 mmoll21 and (V) high-density lipoprotein
(HDL) ,1 mmoll21 in men or ,1.3 mmoll21 in women. Patients
with a history of cardiovascular diseases, pre-existent chronic
inflammatory disease and/or cancer were not included. Normal
controls consisted of subjects who met less than two of the MetS
criteria. These subjects are referred here as healthy subjects (HS).
MP isolation
Peripheral blood (20 ml) from HS and MetS patients was
collected in EDTA-treated tubes (Vacutainers, Becton Dickinson,
Le Pont de Claix, France) from a peripheral vein using a 21-gauge
needle to minimize platelet activation and were processed for assay
within 2 h [12,13]. After a 20 min centrifugation (2706g), platelet-
rich plasma was separated from whole blood. Platelet-rich plasma
was then centrifuged for 20 min (15006g) to obtain platelet-free
plasma (PFP). Two hundred ml of PFP was frozen and stored at –
80uC. Remaining PFP (MP-containing) was spun down at
21,0006g for 45 min to pellet MPs. The MP pellet was then
centrifuged twice at 14,0006g for 45 min. Finally, the MP pellet
was resuspended in 200 ml of 0.9% saline salt solution and stored
at 4uC, as previously described [12,13]. For each healthy subject
or MetS patient, MP concentration in plasma was determined by
flow cytometry. Briefly, an equal volume of sample and Flowcount
beads (Beckman Coulter, Villepinte, France) were added and
samples were analyzed in a flow cytometer 500 MPL System
(Beckman Coulter) [12,13]. Levels of endotoxin were assessed in
all MP preparations with the Limulus amebocyte lysate kit QCL-
1000 (Lonza, Verviers, Belgium) and were found to be below the
lower detection limit of the kit (,0.1 endotoxin Uml21).
For animal treatments, we injected the mice with either
supernatants corresponding to the last MP washing medium
(vehicle) or MPs at the circulating level detected in each donor (HS
and MetS patients). The values of circulating MPs detected in
donors and injected into mice ranged from 1264 and 16734
MPsml21 of plasma for HS and 2575 and 23266 MPsml21 of
plasma for MetS patients. Characterization of MPs by flow
cytometer is shown in Table S1. As previously shown [12], total
circulating levels of MPs and platelet-, endothelial- and red cell-
derived MPs were significantly enhanced when compared with HS
MPs.
Vascular reactivity
Male Swiss mice (8–10 weeks old) were treated in vivo by
intravenous (i.v.) injection into the tail vein with either vehicle or
MPs at the circulating levels of MPs detected in the blood of each
patient (MetS MPs) or healthy subject (HS MPs). Each mouse has
been injected with MPs from one donor. Animals had continuous
access to food and water throughout the experiment and were
maintained on a 12:12 light:dark cycle.
Due to the findings from our preliminary studies in previous
projects investigating MP effects on vascular function that the 24 h
duration was the best time to observe changes at the functional
level for vascular function [23,26,27], we injected the mice with
MPs or vehicle control 24 h prior to being sacrificed by CO2.
After mice were culled, aortas were removed and cleaned of
MP-Induced Hypo-Reactivity in Metabolic Syndrome
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adhering fat and connective tissue and then cut into rings (1.5–
2 mm long) that were mounted on a wire myograph filled with
physiological salt solution as previously described [12,13].
Concentration-response curves were constructed by cumulative
application of serotonin (5-HT, 1 nmoll21 to 10 mmoll21; Sigma-
Aldrich, St. Quentin, Fallavier, France) to vessels with functional
endothelium in the absence or presence of the given inhibitor pre-
incubated for 30 min: the NO-synthase inhibitor NG-nitro-L-
arginine (L-NA, 100 mmoll21; Sigma-Aldrich), the selective
cyclooxygenase (COX)-2 inhibitor N-(2-cyclohexyloxy-4-nitrophe-
nyl) methanesulfonamide (NS-398, 10 mmoll21; Sigma-Aldrich),
indomethacin, the non selective COX inhibitor (100 mmoll21;
Sigma-Aldrich). All inhibitors were used at maximal active
concentrations at which they inhibit the release of either NO
from all isoforms of NO-synthases, metabolites from COX-2
isoform or metabolites from COX in blood vessels, as reported in
many of our previous studies [13,23]. Higher concentrations of L-
NA, NS-398 or indomethacin did not induce further inhibition.
The response to KCl (80 mmoll21) containing thromboxane A2
agonist (9,11-dideoxy-11a,9a-epoxymethanoprostaglandin F2a)
(U46619, 100 nmoll21, Sigma-Aldrich) was also assessed in mice
aortas in order to test their maximal contractile capacity.
In another set of experiments, MetS MPs were pre-incubated
with human anti-FasL antibody (5 mg, BD Biosciences, San Jose,
CA) for 1 h at 4uC to allow neutralization of MP FasL. After two
washes with PBS in order to remove unbound anti-FasL antibody,
MetS MPs were then injected i.v. into mice and 24 h later,
vascular reactivity in response to 5-HT was assessed as described
above.
Determination of prostanoid production
Mice, both pre-treated with MPs and controls were culled and
aortas were dissected, placed in phosphate saline solution PSS and
treated with 5-HT (1 mmoll21, 37uC, 30 min). After collection of
PSS, prostacyclin was measured by enzyme immunoassays kits
(Cayman Chemicals, Ann Arbor, MI). The concentration of
prostanoids was expressed as pgml21 mg21 of tissue (dry weight).
NO determination by electron paramagnetic resonance
(EPR)
Animals were culled 24 h after administration of MPs or
vehicle. For NO production, aortas were dissected and incubated
for 30 min in Krebs-Hepes buffer containing: BSA (20.5 gl21),
CaCl2 (3 mmoll
21) and L-Arginine (0.8 mmoll21). NaDETC
(1.5 mmoll21) and FeSO4.7H2O (1.5 mmoll
21) were separately
dissolved under argon gas bubbling in 10 ml volumes of ice-cold
Krebs-Hepes buffer. These were rapidly mixed to obtain
Fe(DETC)2 solution (0.4 mmoll
21), which was added to the aortas
and incubated for 45 min at 37uC. Aortas were immediately
frozen in plastic tubes using liquid N2. NO measurement was
performed on a table-top x-band spectrometer Miniscope
(Magnettech, MS200, Berlin, Germany). Recordings were made
at 77uK. Instrument settings were 10 mW of microwave power,
1 mT of amplitude modulation, 100 kHz of modulation frequen-
cy, 150 s of sweep time and 5 scans. Signals were quantified by
measuring the total amplitude, after correction of baseline as done
previously [13,23,28].
Dihydroethidine (DHE) staining and reactive oxygen
species (ROS) production
In situ production of ROS in the vessel wall was evaluated with
the oxidative fluorescent dye DHE as previously described [29].
Briefly, aorta sections (7 mm) were mounted on glass slides and
incubated with DHE (3 mmoll21, 30 min, 37uC). A Solamere
confocal equipment with a DLS-300 laser mounted on a Nikon
Eclipse TE 2000-S inverted microscope was used for the optical
sectioning of the tissue. Digital image recording was performed
using the QED in vivo Software. Pixel quantification was executed
by scanning densitometry (Image J software).
Western Blotting
Each aorta was dissected, homogenized and lysed. Proteins
(80 mg) were separated on 10% SDS-PAGE. Blots were probed
with anti-inducible NOS (iNOS) (BD Biosciences), COX-1 and
COX-2 (Santa Cruz Biotehnology, Santa Cruz, CA), Mn-
superoxide dismutase (SOD), Cu/Zn-SOD, extracellular-SOD
(Ec-SOD) (Stressgen Biotechnologies Corporation, Victoria,
Canada), gp91phox, p47phox, p67phox (BD Biosciences), Monocyte
Chemotactic Protein (MCP)-1 (R&D systems, Abingdon, UK)
antibodies. In another set of experiments, total proteins from MetS
MPs were probed with anti-FasL antibody (BD Biosciences).
A polyclonal rabbit anti-human b-actin antibody (Sigma-
Aldrich) was used as a loading control. Membranes were washed
at least three times in Tris-buffer solution containing 0.05%
Tween and incubated for 1 h at room temperature with the
appropriate horseradish peroxidase (HRP)-conjugated secondary
antibody (Amersham, Piscataway, NJ). Protein bands were
detected by enhanced chemiluminescence plus (Amersham)
according to the protocol of the manufacturer. Immunoblots were
quantified by densitometric analysis (LAS3000 software, Fujifilm,
Bois d’Arcy, France).
Quantitative real time reverse transcription-polymerase
chain reaction (RT-PCR) analysis
Aortas taken from mice injected either with vehicle, MetS MPs
or HS MPs were cleaned, frozen in liquid N2 and used to
investigate the expression of mRNA for IL-6, IL-8, IL-1a, IL-1b,
IL-10, TNF-a, MCP-1, TGF-b1, TGF-b2 and TGF-b3 by RT-
PCR. RT-PCR analyses were carried out using a Chromo 4tm
(Bio-Rad, Marnes-la-Coquette, France) and SYBR Green detec-
tion. Quantifications were realized according to the DCt method
as previously described [30].
Data analysis
Data are expressed as mean 6 SEM, and n represents the
number of mice. pD2=2log EC50, EC50 being the molar
concentration of the agonist that produces 50% of the maximal
effect; EC50 values were calculated by log-log regression. Statistical
analyses were performed using ANOVA, and Mann-Whitney U
tests or ANOVA for repeated measures and subsequent Bonfer-
roni post hoc test. P,0.05 was considered to be statistically
significant.
Results
As shown in Table 1, there were no significant differences
between MetS patients and HS with respect to age. As expected,
MetS patients showed greater BMI, visceral obesity (as measured
by waist circumference), enhanced triglyceridemia, and increased
blood pressure. HbA1c values were not higher than 7.5% both in
MetS patients and HS. Insulin levels were significantly higher in
MetS patients, indicating insulin resistance. In addition, MetS
patients exhibited lower levels of adiponectin compared to control
subjects, although leptin levels were similar in both groups,
supporting insulin resistance within the MetS patients [31]. Over
half of the MetS patients exhibited 4 out of 5 MetS criteria
(Table 1).
MP-Induced Hypo-Reactivity in Metabolic Syndrome
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Consistent with our previous findings [12], we found that total
circulating levels of MPs and platelet-, endothelial- and red cell-
derived MPs were significantly enhanced when compared with HS
MPs (Table S1).
MetS MPs induce ex vivo vascular hypo-reactivity in
mouse aorta
5-HT produced a concentration-dependent increase in tension
in aortic rings from all groups of mice; however, vascular reactivity
to the agonist was markedly decreased in mice treated with MetS
MPs compared to those treated with either vehicle or HS MPs
(Fig. 1A). Interestingly, the aortas from MetS MP-treated mice,
compared to those from vehicle- or HS MP-treated animals, also
exhibited an impaired contractile response to the concomitant
application of KCl (80 mmoll21) and a single concentration of
another vaso-constrictor agonist, thromboxane A2 agonist U46619
(100 nmoll21) (Fig. 1B). These data suggest that the MetS MP-
induced vascular hypo-reactivity is agonist-independent.
Involvement of NO in MetS MP-induced vascular hypo-
reactivity
To investigate the role of NO, the effect of the NO-synthase
inhibitor, L-NA, was studied in response to 5-HT treatment.
Interestingly, we found that inhibition of the NO pathway
completely prevented the vascular hypo-reactivity induced by
MetS MPs (Fig. 2A), suggesting that NO may be involved in the
mechanism of this vascular hypo-reactivity. Direct in situ
measurements of NO production were performed by EPR
spectroscopy using Fe(DETC)2 as a spin trap. Aortas from vehicle,
HS MP- and MetS MP-treated mice, exhibited an EPR feature of
signals derived from NO-Fe(DETC)2. The NO-Fe(DETC)2 EPR
signal was greater in aortas from MetS MPs-treated mice
compared to vehicle- and HS MP-treated mice (Fig. 2B).
Moreover, MetS MPs markedly increased iNOS expression in
mouse aorta compared to vehicle or HS MPs (Fig. 2C) indicating
elevated enhanced NO production.
MetS MPs increase ROS production and increase NADPH
oxidase expression
Aorta sections from mice treated with MetS MPs displayed an
increase in vascular wall (endothelium and in the media layer)
ROS production compared to vessels from vehicle or HS MP-
treated mice, measured through EtBr fluorescence (Fig. 3A).
We evaluated expression of membrane (gp91phox) and cytosolic
(p47phox and p67phox) subunits of NADPH oxidase, a major source
Table 1. Baseline characteristics of subjects.
Control subjects MetS patients
Number 17 21
Mean age (years) 5462 5662
Sex ratio (male/female) 12/5 17/4
BMI (kg/m2) 2861.3 3461.1c
Waist circumference (cm) 9463.2 11362.3c
Ratio Waist/Hips 0.9560.02 1.0160.01a
Systolic blood pressure (mm Hg) 12162 13563c
Diastolic blood pressure (mm Hg) 7462 7962a
Glycemia (mmol/l) 5.3360.11 6.5560.22c
Insulinemia (pmol/l) 61.669.1 163.7617.8c
HbA1c (%) 5.660.06 6.1760.24a
Total cholesterol (mmol/l) 660.34 5.360.25
HDL cholesterol (mmol/l) 1.9260.16 1.6360.13
LDL cholesterol (mmol/l) 3.260.26 2.6460.21
Triglycerides (mmol/l) 1.360.11 2.4260.33c
Leptin (mg/l) 15.364.8 15.263.11
Adiponectin (mg/l) 8.160.8 5.360.34b
Number of MetS components (%)
0 36 -
1 41 -
2 23 -
3 - 38
4 - 52
5 - 10
Treatments (%)
Oral antidiabetic 0 41
Insulin 0 2
Antihypertensive 1 70
Statins 2 2
Baseline characteristics of MetS patients (n=21) compared to control subjects
(n= 17). Subjects were fasted before blood collection. All values are expressed
in International System (SI) units.
aP,0.05;
bP,0.01;
cP,0.001.
doi:10.1371/journal.pone.0027809.t001
Figure 1. MetS MPs induce vascular hypo-reactivity in mouse aortas. Concentration-response curves to 5-HT (A) and contractile response to
the concomitant application of KCl and a single concentration of U46619 (B) in aortic rings from mice treated with either vehicle (CTL, n= 7), healthy
subject MPs (HS MPs, n= 8) or MetS patient MPs (MetS MPs, n=8). ***P,0.001 MetS MPs vs. CTL; ## P,0.001 MetS MPs vs. HS MPs.
doi:10.1371/journal.pone.0027809.g001
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of cellular superoxide anion (O2
2). Interestingly, MetS MPs
markedly enhanced the expression of gp91phox, as well as p47phox
without affecting the level of p67phox in mouse aorta (Fig. 3B),
accounting probably for an increase in NADPH oxidase activity,
while vehicle or HS MPs produced no effect. To evaluate the
capacity of the vessels to reduce O2
2 in the presence of MPs, we
examined expression of different isoforms of SOD. MPs from both
HS and MetS patients did not significantly affect Mn-SOD, Cu/
Zn-SOD or Ec-SOD expression compared to the vehicle control
(Fig. 3C).
Involvement of COX metabolites in MetS MP-induced
vascular hypo-reactivity
To investigate the role of COX metabolites in 5-HT-induced
vaso-reactivity, the effects of both a non-selective inhibitor of
COX (indomethacin) and a selective inhibitor of COX-2 (NS398),
were examined.
In the presence of indomethacin, contractile response to 5-HT
was reduced in aortas from all groups of mice (Fig. 4A–4C). Thus,
vascular hypo-reactivity to 5-HT was still present in aortas from
mice treated with MetS MPs compared to HS MPs or vehicle.
These results highlight that vasoconstrictor metabolite(s) sensitive
to indomethacin participate in 5-HT-induced contraction
(Fig. 4D). When COX-2 was specifically inhibited using NS398,
the response to 5-HT was impaired in vessels from vehicle and HS
MP injected mice (Fig. 4E–4F), suggesting the contribution of
COX-2-derived vasoconstrictor metabolites. By contrast, inhibi-
tion of COX-2 did not modify the response induced by MetS MPs
(Fig. 4G). These results suggest that MetS MPs treatment leads to
the release of both vasodilator and vasoconstrictor metabolites and
the former blunted the effect of the latter. Interestingly, MetS MPs
enhanced the production of prostacyclin, a vasorelaxant metab-
olite, independently of modification in either COX-1 or COX-2
expressions (Fig. 5B).
MetS MPs increase MCP-1 expression in mice aortas
In order to evaluate the effect(s) of MPs on inflammatory
processes, we analyzed the mRNA expression of pro-inflammatory
cytokines. As shown in Table 2, MetS MPs increased the
expression of MCP-1, a potent agonist of monocytes, memory T
cells, and basophils. However, MPs either from MetS patients or
HS had no effect on mRNA expression of TGF-b1, TGF-b2 and
TGF-b3 (Table 2). The mRNA expression of the other cytokines
(IL-6, IL-8, IL-1a, IL-1b, IL-10 and TNF-a) was not detectable
under the experimental conditions used. MCP-1 mRNA increase
was reinforced by our observation that aortas from mice treated
with MetS MPs exhibited enhanced MCP-1 protein expression
compared to those from mice treated either with vehicle or HS
MPs (Fig. 6D).
Involvement of Fas/FasL signaling pathway in the
vascular MetS MP-induced hypo-reactivity
Interestingly, we found that MPs from MetS patients expressed
FasL (Fig. 6A). When we neutralized FasL harbored by MetS
MPs, using specific antibodies, prior to their injection into mice,
we completely prevented the hypo-reactivity previously observed
in mouse aorta (Fig. 6B). This indicates that Fas/FasL pathway is
involved in MP-induced vascular dysfunction. Interestingly,
neutralizing FasL also prevented the MetS MP-induced increase
of iNOS (Fig. 6C) and MCP-1 (Fig. 6D).
Figure 2. Involvement of NO in MetS MP-induced vascular
hypo-reactivity. (A) Concentration-response curves to 5-HT of aortic
rings from mice treated with either vehicle (CTL, n= 7), HS MPs (n= 8),
or MetS MPs (n=8) in the presence of NO-synthase inhibitor (L-NA,
100 mmol/l). (B) Quantification of the amplitude of NO-Fe(DETC)2 signals
in aorta from mice treated with either vehicle, HS MPs or MetS MPs.
Values are expressed as units/mg weight of dried (dW) aorta (n= 7). (C)
Western blot revealing expression of inducible NO-synthase (iNOS) in
aorta from mice treated with either vehicle, HS MPs or MetS MPs. Data
are expressed as denstometry in arbitrary units (A.U.) as mean 6 SEM.
* P,0.05 vs. CTL;# P,0.05 MetS MPs vs. HS MPs;## P,0.01 MetS MPs
vs. HSMPs.
doi:10.1371/journal.pone.0027809.g002
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Discussion
In the present study, we demonstrated that i.v. injection of MetS
MPs promotes vascular hypo-reactivity in mice. This may be an
effect of the release of vasodilatory products from different cellular
origins (for example endothelial cells, smooth muscle cells, or
fibroblasts). Interestingly, we found that the observed vascular
hypo-reactivity was associated with overproduction of vasodilator
mediators, such as NO and prostacyclin, as well as increased ROS
in the aorta. These effects resulted in an up-regulation of iNOS
without changes in COX-1 and COX-2 expression, and enhanced
expression of the NADPH-oxidase subunits, gp91phox and p47phox.
Of particular interest is the finding that Fas/FasL pathway is
involved in MetS MP-induced vascular hypo-reactivity. MetS MPs
also markedly increased MCP-1 mRNA and protein levels,
without changing the mRNA levels of other pro-inflammatory
cytokines in the aorta. These data provide valuable information in
our understanding of some of the paracrine roles that MPs play as
vectors of trans-cellular messengers in promoting vascular
dysfunction during MetS.
MPs contribute, at least in part, to the alterations of vascular
function in many cardiovascular diseases (for review [7,9,32]). In
our previous work [12], we showed that MetS patients had
increased circulating levels of MPs compared to HS. In particular,
we observed an increase in endothelial-, erythrocyte-, and platelet-
derived MPs in addition to pro-coagulant (annexin V+) MPs in
MetS patients. We also reported previously an association between
increased circulating MPs and their properties in inducing
endothelial dysfunction both in vitro and in vivo. We showed that
the effect of MetS MPs on endothelial cells is driven by non
platelet-derived MPs [12]. In the present study, total circulating
MPs from HS or MetS patients were injected into mice, in order to
mimic the in vivo situation where all subpopulations of MPs co-
exist. Interestingly, we provide further evidence that MetS MPs
are also able to promote vascular hypo-reactivity in response to
vaso-constrictor agonists in mice aortas. These findings are in line
with our previous studies where MPs generated in vitro from
apoptotic T lymphocytes or MPs obtained either from diabetic
patients [23] or pre-eclamptic women [27,33] induced vascular
hypo-reactivity in mice aortas. In these previous studies, vascular
hypo-reactivity was observed even in vessels without functional
endothelium. In addition, lymphocyte-derived MPs injected in vivo
were able to interact directly with smooth muscle as evidenced by
an increased CD4 labelling in the media layer of aortas from MP-
Figure 3. MetS MPs increase ROS production and enhance NADPH oxidase expression. (A) Detection of ROS production in the vascular
wall. Vessel sections of aorta from mice treated with either vehicle, HS MPs or MetS MPs were incubated 30 min with DHE and visualized by confocal
microscopy. Results are representative pictures of three independent experiments. Bargraphs show the quantification of ROS. Typical examples of
ROS staining in each group are shown. (B and C) Western blots revealing expression of NADPH oxidase subunits (gp91phox, p47phox and p67phox) (B)
and expression of SOD isoforms (Mn-SOD, Cu/Zn-SOD and Ec-SOD) (C) in aorta from mice treated with either vehicle, HS MPs or MetS MPs. Data are
expressed as denstometry in arbitrary units (A.U.) as mean 6 SEM. * P,0.05 vs. CTL; ** P,0.01 vs. CTL # P,0.05 vs. HS MPs; ## P,0.01 vs. HSMPs.
doi:10.1371/journal.pone.0027809.g003
Figure 4. Involvement of COX metabolites in MetS MP-induced vascular hypo-reactivity. (A–D) Concentration-response curves to 5-HT of
aortic rings from mice treated with either vehicle (CTL, n= 7), HS MPs (n= 8) or MetS MPs (n= 8) in the absence or presence of COX inhibitor
(indomethacin, 10 mmol/l). (E–H) Concentration-response curves to 5-HT of aortic rings from mice treated with either vehicle (CTL, n=7), HS MPs
(n=8) or MetS MP (n= 8) in the absence or presence of COX-2 inhibitor (NS398, 1 mmol/l). ***P,0.001 vs. absence of the inhibitor; ## P,0.01 MetS
MPs vs. CTL.
doi:10.1371/journal.pone.0027809.g004
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treated mice compared to control vessels. Furthermore, the same
MPs were able to induce iNOS and COX-2 expression in cultured
human smooth muscle cells in vitro [23,34]. In another study, in vivo
injection of mice or ex vivo incubation with circulating MPs from
pre-eclamptic women reduced contraction to 5-HT in mice aortas
[27]. Together, these results suggest that MetS MPs are able to
induce the release of vasodilatory factors from smooth muscle cells.
However, we cannot exclude that injection of MetS MPs facilitates
the in vivo interaction between platelets and vessel wall of mice, and
the subsequent induction of iNOS and COX-2 in smooth muscle
cells that was observed ex vivo. Alternatively, MetS MPs can evoke
an alteration in the balance between the relaxant and constricting
factors in smooth muscle cells.
In regards to vasodilatory factors, vascular hypo-reactivity
induced by MetS MPs was accompanied by increased NO
production and enhanced expression of iNOS, as well as an
increased release of prostacyclin. Interestingly, the inhibition of
NOS with L-NA completely prevented MetS MP-induced
vascular hypo-reactivity, indicating a crucial role of NO in MetS
MP-mediated effects. Previously, we showed that MetS MPs
reduced eNOS expression in mouse aortas [12]. Traditionally, the
up-regulation of iNOS is thought to compensate for the loss of
functional endothelium and eNOS during injury and atheroscle-
rosis [35], although the presence of excess NO and ROS
coincidentally may lead to additional tissue damage and
dysfunction. Accordingly, Tesse et al. [23] have shown that MPs
from T lymphocytes enhanced expression of iNOS and COX-2
with subsequent increased NO and prostacyclin productions, and
reduce the vascular contractility to agonists. It has also been shown
that MPs from pre-eclamptic women enhance NO production in
mouse aortas and that NOS inhibition strongly enhances the
response to 5-HT in vessels from mice treated with MPs from pre-
eclamptic women [27,36].
ROS play an important role in the development of cardiovas-
cular diseases, including hypertension, atherosclerosis, stroke,
ischemia-reperfusion injury and diabetes [37]. The main enzymatic
source of ROS that is important in vascular disease and
hypertension is NADPH oxidase [38]. Here, we report that MetS
MPs, in addition to increased NO release, led to increases in the
expression of membrane (gp91phox) and regulatory cytosolic
(p47phox) subunits participating in the activation of NADPH oxidase
activity and O2
2 overproduction. At this stage we are unable to
exclude mitochondria as another source of ROS generation.
The aortic contraction in response to 5-HT involved the
participation of COX-1 vasoconstrictor metabolites independently
of the treatment (vehicle, HS MPs or MetS MPs) indicating that
COX-1 metabolites did not affect the capacity of MetS MPs to
promote vascular hypo-reactivity. Interestingly, the blockade of
COX-2 using a specific inhibitor resulted in a reduced response to
5-HT stimulation in aortas from vehicle-treated and in those from
HS MP-treated but not in MetS MP-treated mice. In regards to
COX-1 and COX-2 expression, we found no significant
differences between aortas taken from mice treated either with
vehicle, HS MPs or MetS MPs. These results suggest the existence
of a vasoconstrictor metabolite probably from COX-1, which is
implicated in the pathway activated by the agonist in mouse aortas
independent of MetS MPs treatment inasmuch the same inhibition
was observed either in control or in vessels from HS MPs-treated
mice. The fact that inhibition of COX-2 caused no effect in vessels
from MetS MP-treated mice suggests that this enzyme is not
involved in the process. Alternatively, MetS MPs activate COX-2
leading to a release of vasodilator metabolites that are compen-
Figure 5. MetS MPs increase prostacyclin release from mouse aorta. (A) Concentration of the COX derivative, prostacyclin in the
supernatants of mouse aorta pre-treated with either vehicle (CTL), HS MPs, or MetS MPs (n values?) and stimulated with 5-HT (n=5). (B) Western blots
revealing expression of COX-1 and COX-2 in aorta from mice treated with either vehicle (CTL), HS MPs, MetS MPs. Data are expressed as denstometry
in arbitrary units (A.U.) as mean 6 SEM. *P,0.05 MetS MPs vs. CTL; # P,0.05 MetS MPs vs. HS MPs.
doi:10.1371/journal.pone.0027809.g005
Table 2. Quantitative real time RT-PCR analysis.
mRNA normalized relative quantity (6103)
CTL HS MPs MetS MPs
MCP-1 104628 51616 201617a,b
TGF-b1 32266377 33826481 29606331
TGF-b2 3367.5 28.766.6 2867.3
TGF-b3 38736731 31686485 36006713
Quantitative real time RT-PCR analysis of normalized relative quantity of IL-6, IL-
8, IL-1a, IL-1b, TNF-a, MCP-1, TGF-b1, TGF-b2 and TGF-b3 mRNA expressions in
mouse aorta after 24 h of i.v. injection with either vehicle (CTL, n=4), MPs from
healthy subjects (HS MPs, n= 4) or MPs from MetS patients (MetS MPs, n= 4).
The mRNA: IL-6, IL-8, IL-1a, IL-1b, IL-10 and TNF-a was not detectable under the
experimental conditions used.
aP,0.05 vs. CTL;
bP,0.01 vs. HS MPs.
doi:10.1371/journal.pone.0027809.t002
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sated by a release of vasoconstrictor metabolites. The latter
hypothesis is supported by the fact that MetS MPs, but not HS
MPs, were able to induce an increase in the release of prostacyclin.
It is possible that under the conditions studied, prostacyclin may
attenuate the vascular damage induced by NO overproduction,
and may participate to the adaptive response of vascular cells to
MetS MPs.
Evidences from clinical and experimental studies support the
hypothesis that inflammation plays an important role in a wide
range of cardiovascular diseases and have focused attention on the
signals that initiate cellular infiltration of vascular tissues [31,39].
In the current study, we report that MetS MPs increased vascular
expression of MCP-1, which could potentially lead to increased
recruitment of leukocytes under conditions associated with
vascular inflammation. Previously, we reported that MetS MPs
did not affect in vitro expression of MCP-1 mRNA in cultured
endothelial cells [12]. A possible reason for this discrepancy may
be due to additional interactions between MetS MPs and
circulating cells following injection into mice.
FasL is a 40-kDa cytotoxic type II trans-membrane protein
belonging to the tumour necrosis factor1 family. Unlike Fas, which
is constitutively expressed by various cell types, FasL is expressed
primarily by cells of the immune system such as activated T cells
[18,40]. Fas and FasL play a crucial role in the induction of
apoptosis in various cell types [18,40]. By deleting auto-reactive
lymphocytes, Fas/FasL ensure the development of normal T and
B cell repertoires [18,40], preventing autoimmune disorders. In
vascular smooth muscle cells, it has been shown that the activation
of the Fas/FasL pathway results in the increased expression of a
specific program of inflammatory genes [21,22]. Functionally,
FasL has been shown to be pro-inflammatory, and implicated in
pathophysiological processes of various cardiovascular diseases,
such as coronary heart disease, arteriosclerosis, and ischemia-
reperfusion injury [19]. In human atherosclerosis, FasL is
expressed together with markers of apoptosis in inflammatory
regions of plaques [41]. FasL-mediated smooth muscle cell
apoptosis within the vulnerable plaque may lead to plaque
instability and rupture, events well known to cause myocardial
infarction and stroke. Given the role of the pro-inflammatory
pathway Fas/FasL in the expression of inflammatory genes in
smooth muscle cells [21,22], we hypothesized that the vascular
effects of MetS MPs may be mediated by the interaction of FasL,
harbored by MetS MPs, and Fas receptor expressed by smooth
muscle cells from the vascular wall [41]. In the present study, we
find that MetS MPs express FasL and that its neutralization, using
a specific antibody, restores the reactivity in vessels from MetS
MP-injected mice towards reactivity of aortas either from vehicle-
or HS MP-treated mice. Interestingly, neutralization of FasL also
normalizes the expression of iNOS and MCP-1 in aortas from
MetS MP-treated mice indicating the importance of inflammation
and NO in MetS MPs effects. In line with our findings, it has been
reported that proapoptotic stimuli, including FasL, or over-
Figure 6. Involvement of Fas/FasL signaling pathway in the MetS MP-induced hypo-reactivity in mouse aorta. (A) Western Blot
showing FasL expression in MPs obtained from two different patients (P1 and P2). (B) Concentration-response curves to 5-HT of aortic rings from mice
treated with vehicle (CTL, n= 7), MetS MPs (n= 8), or MetS MPs pre-incubated with FasL antibody (n= 6). (C–D) Western Blots showing iNOS (C) and
MCP-1 (D) expressions in aorta from mice treated with either vehicle, HS MPs MetS MPs, or MetS MPs pre-incubated with FasL antibody. Data are
expressed as denstometry in arbitrary units (A.U.) as mean 6 SEM. ***P,0.001 vs. CTL; # P,0.05 vs.HS MPs; P,0.001 vs.HS MPs; 1 P,0.05 vs. MetS
MPs + FasL antibody; 11 P,0.01 vs. MetS MPs + FasL antibody.
doi:10.1371/journal.pone.0027809.g006
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expression of Fas-associated death domain protein causes local
accumulation of macrophages and triggers transcriptional upre-
gulation of MCP-1 in vitro and in vivo [21] through a mechanism
involving calpains and caspase 8 [22]. Furthermore, Fas/FasL
interaction is capable to induce NFkB signalling [40] and may
therefore induce iNOS expression [42]. The fact that we found
that neutralizing FasL carried by MPs prevented vascular
dysfunction supports of the hypothesis of an interaction between
FasL from MetS MPs with Fas from the vessel wall of the treated/
injected mouse. In support of this, we showed previously that MPs
injected in vivo are able to interact directly with smooth muscle by
increasing CD4 labelling in the media layer of aortas from MP-
treated mice compared to vessels from control mice [23].
Interestingly, in the current study we noticed that MetS MPs did
not affect the sensitivity to vasoconstrictors as shown by the
absence of differences in the pD2. Nevertheless, MetS MPs act via
other pathways, including but not limited to Fas/FasL, to increase
vascular inflammation and enhance release of vasodilator agents
(NO, prostacyclins) which participate in decreasing the Emax
(hypo-reactivity).
In conclusion, we provide evidence that MetS MPs induce ex
vivo vascular hypo-reactivity to vasoconstrictor agents in aorta by
increasing both oxidative and nitrosative stresses and by increasing
the release of COX-2-derived prostacyclin. In addition, we show
that MetS MPs increase the expression of MCP-1 mRNA in the
vessel wall. The critical role of MPs as a vector of biological
messages leading to vascular dysfunction in MetS involving Fas/
FasL pathway is also underlined.
These effects of MetS MPs, in addition to their capacity to
reduce endothelial vasodilatation, strengthen the notion that MPs
cannot only be considered as surrogate markers of endothelial
dysfunction or injury, but also as effectors able to amplify pre-
existing vascular dysfunction, including vascular hypo-reactivity
and inflammation. Thus, MetS MPs may interfere with mecha-
nisms leading to atherosclerotic plaque development and vascular
thrombosis during the evolution of MetS.
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